【摘要】：研究背景及目的上皮性卵巢癌患者五年生存率低的一個重要原因是由于患者對抗腫瘤藥物出現(xiàn)耐藥,即化療藥物所誘導(dǎo)的腫瘤細(xì)胞凋亡被抑制。XIAP被認(rèn)為是迄今為止作用最強(qiáng)的內(nèi)源性抗凋亡蛋白,在多種腫瘤組織中高表達(dá),但其在卵巢癌組織中表達(dá)失調(diào)的分子作用機(jī)制還不清楚。微小RNA(miRNA)是一類高度保守的非編碼小分子RNA,在腫瘤的發(fā)生、發(fā)展及耐藥性的形成中起重要作用。故篩選出與XIAP相互作用的miRNA,闡述其參與凋亡調(diào)節(jié)的分子機(jī)制非常重要,不僅將揭示一個全新的由miRNA介導(dǎo)的遺傳信息調(diào)控網(wǎng)絡(luò),也為腫瘤的早期診斷、療效評估以及疾病預(yù)后的分析提供重要分子依據(jù),為腫瘤治療提供新的潛在靶點(diǎn)。方法1.免疫組化及免疫印跡檢驗(yàn)XIAP在卵巢癌組織及對照卵巢組織中的表達(dá)情況;2.在卵巢癌細(xì)胞中,用慢病毒過表達(dá)XIAP或RNA干擾技術(shù)(siRNA)降低XIAP的表達(dá),觀察細(xì)胞凋亡情況;3.運(yùn)用生物信息學(xué)軟件預(yù)測靶向XIAP基因3'UTR的miRNA。綜合文獻(xiàn)報道,從預(yù)測的結(jié)果中找出在卵巢癌組織中低表達(dá)的miRNA,用雙熒光素酶報告基因和miRNA表達(dá)載體共轉(zhuǎn)染293T細(xì)胞方式進(jìn)行篩選和驗(yàn)證。4.選取經(jīng)驗(yàn)證的作用效果強(qiáng)的miR-155和miR-137,分別用作用位點(diǎn)突變、熒光定量PCR、免疫印跡、siRNA和細(xì)胞凋亡的功能實(shí)驗(yàn)進(jìn)一步明確每個miRNA對順鉑誘導(dǎo)的卵巢癌細(xì)胞凋亡的影響及可能機(jī)制,并在卵巢癌組織樣本及細(xì)胞系中對miR-137與XIAP的表達(dá)水平進(jìn)行相關(guān)性分析。結(jié)果1.XIAP在上皮性卵巢癌組織中高表達(dá)。在卵巢癌細(xì)胞系SKOV3中過表達(dá)XIAP可抑制順鉑誘導(dǎo)的細(xì)胞凋亡,而降低XIAP的表達(dá)則作用相反。2.綜合軟件預(yù)測與文獻(xiàn)報道的結(jié)果,發(fā)現(xiàn)既與XIAP 3'UTR有相互作用又在卵巢癌組織中低表達(dá)的候選miRNA共22個,用雙熒光素酶報告基因篩選出其中8個miRNA與XIAP 3'UTR確有相互作用,其中miR-137,miR-155,miR-142及miR-146a的作用明顯。3.針對作用很強(qiáng)的miR-155和miR-137,本實(shí)驗(yàn)發(fā)現(xiàn)它們均可以降低卵巢癌細(xì)胞SKOV3、A2780的順鉑IC50值,并促進(jìn)卵巢癌細(xì)胞系及原代培養(yǎng)癌細(xì)胞的順鉑所誘導(dǎo)的細(xì)胞凋亡。位點(diǎn)突變和凋亡功能回復(fù)實(shí)驗(yàn)都說明是直接通過作用于XIAP 3'UTR來抑制XIAP蛋白表達(dá)的。區(qū)別于miR-155,miR-137與XIAP 3'UTR有兩個作用位點(diǎn)。進(jìn)一步分析卵巢癌組織與正常對照樣本的結(jié)果,顯示XIAP在卵巢癌組織中表達(dá)水平明顯升高,miR-137的表達(dá)水平顯著降低,并且兩者的表達(dá)水平負(fù)相關(guān)。結(jié)論XIAP在上皮性卵巢癌組織中表達(dá)水平明顯升高,并能抑制卵巢癌細(xì)胞對順鉑的敏感性,提示XIAP與卵巢癌的發(fā)生發(fā)展相關(guān),是導(dǎo)致卵巢癌化療耐藥的重要原因之一。低表達(dá)的miRNA是導(dǎo)致XIAP在卵巢癌組織中表達(dá)升高的重要原因。由于其中的miR-155和miR-137能夠促進(jìn)順鉑所致的細(xì)胞凋亡,說明這些miRNA很可能通過調(diào)節(jié)XIAP的表達(dá),參與了卵巢癌細(xì)胞凋亡的調(diào)控和卵巢癌化療耐藥的形成,因而這些miRNA的表達(dá)異�？赡苁锹殉舶┗熌退幍臋C(jī)制之一,并可能成為開發(fā)新的化療藥物的潛在靶點(diǎn)。
[Abstract]:One important reason for the low five-year survival rate of the study background and target epithelial ovarian cancer is that the patient's resistance to the tumor drug, i.e., the tumor cell apoptosis induced by the chemotherapy drug, is suppressed. XIAP is considered to be the most potent endogenous anti-apoptotic protein to date and is highly expressed in a variety of tumor tissues, but the molecular mechanism of the expression of disorders in ovarian cancer tissues is not clear. MicroRNA (miRNA) is a highly conserved non-coding small-molecule RNA, which plays an important role in the formation, development and drug resistance of the tumor. Therefore, the miRNAs interacting with the XIAP are screened, and the molecular mechanism involved in the regulation of apoptosis is very important, not only a novel miRNA-mediated genetic information regulation network is disclosed, but also an important molecular basis is provided for the early diagnosis of the tumor, the evaluation of the curative effect and the analysis of the prognosis of the disease, and provides a new potential target for tumor therapy. Method 1. The expression of XIAP in ovarian and control ovarian tissues was examined by immunohistochemistry and immunoblotting. In ovarian cancer cells, the expression of XIAP was reduced with lentiviral overexpression of XIAP or RNA interference technology (siRNA), and the cell apoptosis was observed; 3. The miRNAs targeting the XIAP gene 3 'UTR were predicted using bioinformatics software. According to the comprehensive literature, the low-expression miRNAs in the ovarian cancer tissues were identified from the predicted results, and 293T cells were co-transfected with the double-luciferase reporter gene and the miRNA expression vector for screening and verification. selecting the miR-155 and the miR-137 with strong action effect, respectively using the functional experiments of the action site mutation, the fluorescence quantitative PCR, the immunoblotting, the siRNA and the cell apoptosis to further clarify the effect of each miRNA on the apoptosis of the cisplatin-induced ovarian cancer cell and the possible mechanism, The expression levels of miR-137 and XIAP in ovarian cancer tissue samples and cell lines were analyzed. Results 1. XIAP was highly expressed in epithelial ovarian cancer tissues. Overexpression of XIAP in ovarian cancer cell line SKOV3 can inhibit the apoptosis of cisplatin-induced cells, while reducing the expression of XIAP is opposite. The results of the comprehensive software prediction and the literature report show that there are 22 candidate miRNAs that interact with the XIAP 3' UTR and low expression in the ovarian cancer tissues, and 8 miRNAs are screened by the double-luciferase reporter gene, and the action of the miR-137, the miR-155, the miR-142 and the miR-146a is obvious. In response to the very strong miR-155 and miR-137, the experiments have found that they can reduce the cisplatin IC50 value of the ovarian cancer cell SKOV3 and A2780, and promote the cell apoptosis induced by the cisplatin of the ovarian cancer cell line and the primary culture cancer cell. Both site mutation and apoptotic function response experiments demonstrated the direct inhibition of XIAP protein expression by acting on XIAP 3 'UTR. The difference between miR-155, miR-137 and XIAP 3' UTR has two active sites. The results showed that the expression level of XIAP was significantly higher in the ovarian cancer tissues, and the expression level of miR-137 was significantly reduced, and the expression level of the two was negatively correlated. Conclusion The expression of XIAP in epithelial ovarian cancer is significantly higher, and it can inhibit the sensitivity of the ovarian cancer cell to cisplatin, and it is suggested that XIAP is related to the development of ovarian cancer, which is one of the most important reasons leading to the chemotherapy resistance of ovarian cancer. Low-expression miRNAs are an important cause of the increase in the expression of XIAP in ovarian cancer tissues. Because of the fact that the miR-155 and the miR-137 are capable of promoting the apoptosis of the cells caused by cisplatin, the miRNA is very likely to be involved in the regulation of the apoptosis of the ovarian cancer cells and the formation of the ovarian cancer chemotherapy resistance by adjusting the expression of the XIAP, so that the expression of the miRNAs can be one of the mechanisms of the chemotherapy resistance of the ovarian cancer, and may be a potential target for developing new chemotherapeutic agents.
【學(xué)位授予單位】：南方醫(yī)科大學(xué)
【學(xué)位級別】：博士
【學(xué)位授予年份】：2017
【分類號】：R737.31

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 仲任,黃瑞濱,宋善俊;組織因子途徑抑制物2抑制卵巢癌細(xì)胞浸潤轉(zhuǎn)移的體外研究[J];中華婦產(chǎn)科雜志;2003年10期

2 劉爽;林靜嫻;劉琦;石群立;王建東;吳元赭;;維A酸干預(yù)前后卵巢癌細(xì)胞中維A酸受體的表達(dá)變化及意義[J];醫(yī)學(xué)研究生學(xué)報;2007年11期

3 ;發(fā)現(xiàn)休眠卵巢癌細(xì)胞存活機(jī)制[J];生命世界;2009年02期

4 ;美發(fā)現(xiàn)休眠卵巢癌細(xì)胞存活機(jī)制[J];醫(yī)學(xué)研究雜志;2009年04期

5 向君彥;夏新蜀;王昕娜;徐靜;王萍;江園;余和平;白定群;許川山;;低強(qiáng)度中頻超聲殺傷卵巢癌細(xì)胞的初步研究[J];激光雜志;2011年01期

6 陳韻仙;;下泌尿道切除作為卵巢癌細(xì)胞減少術(shù)的一部分[J];國外醫(yī)學(xué).婦產(chǎn)科學(xué)分冊;1983年03期

7 仲任,黃瑞濱,宋善俊;組織因子途徑抑制物2對卵巢癌細(xì)胞遷徙和浸潤能力的影響[J];癌癥;2003年10期

8 ;精液能夠殺死卵巢癌細(xì)胞[J];發(fā)明與創(chuàng)新;2003年12期

9 高琨,李力,陳心秋,張瑋;雌孕激素對卵巢癌細(xì)胞體外生長的影響[J];腫瘤防治研究;2004年04期

10 王威廉,陳心秋,恩帝安,馬加薩,周德南,唐凱,黃薇;抗卵巢癌細(xì)胞膜抗體對卵巢癌細(xì)胞體外細(xì)胞毒性試驗(yàn)及荷瘤小鼠的體內(nèi)聚集性的實(shí)驗(yàn)研究[J];廣西醫(yī)科大學(xué)學(xué)報;2004年04期

相關(guān)會議論文 前10條

1 王文霞;孔北華;李鵬;曲迅;;蛋白酶體抑制劑對卵巢癌細(xì)胞的作用機(jī)制[A];第八次全國婦產(chǎn)科學(xué)學(xué)術(shù)會議論文匯編[C];2004年

2 劉娟娟;林蓓;趙越;李飛飛;郝瑩瑩;張帆;朱連成;張淑蘭;;巖藻糖基化抗原對卵巢癌細(xì)胞生物學(xué)行為的影響[A];東北三省第四屆婦產(chǎn)科學(xué)術(shù)會議論文匯編[C];2008年

3 陳心秋;王威廉;趙芳芳;周德南;唐凱;;~(131)Ⅰ—抗卵巢癌抗體聯(lián)合外放射對卵巢癌細(xì)胞的體外殺傷實(shí)驗(yàn)研究[A];第七屆廣西腫瘤學(xué)術(shù)年會論文匯編[C];2003年

4 王威廉;陳心秋;恩帝安.馬加薩;周德南;唐凱;;抗卵巢癌抗體對卵巢癌細(xì)胞體外細(xì)胞毒及載瘤裸鼠體內(nèi)聚集性實(shí)驗(yàn)研究[A];第七屆廣西腫瘤學(xué)術(shù)年會論文匯編[C];2003年

5 許沈華;牟瀚舟;顧琳慧;朱赤紅;劉祥麟;;高轉(zhuǎn)移卵巢癌細(xì)胞差異表達(dá)基因在染色體定位及其功能[A];浙江省生理科學(xué)會2006年學(xué)術(shù)年會論文匯編[C];2006年

6 唐東平;陳心秋;唐凱;張潔清;賀海平;;11種化療藥物對卵巢癌細(xì)胞的抑制作用及其有核細(xì)胞細(xì)胞毒性研究[A];第四屆中國腫瘤學(xué)術(shù)大會暨第五屆海峽兩岸腫瘤學(xué)術(shù)會議論文集[C];2006年

7 李曉峰;王欣;馬開東;劉寶林;;卵巢癌細(xì)胞的低溫保存及致死特性研究[A];上海市制冷學(xué)會2007年學(xué)術(shù)年會論文集[C];2007年

8 梁念慈;何太平;覃燕梅;吳科鋒;;抗癌草藥半邊旗有效成分對卵巢癌細(xì)胞基因表達(dá)的影響[A];第十屆全國生化與分子藥理學(xué)術(shù)會議論文摘要匯編[C];2007年

9 郝瑩瑩;林蓓;趙越;歐陽玲;張淑蘭;;α1,2巖藻糖轉(zhuǎn)移酶基因轉(zhuǎn)染對卵巢癌細(xì)胞生物學(xué)行為的影響[A];中華醫(yī)學(xué)會第九次全國婦科腫瘤學(xué)術(shù)會議論文匯編[C];2006年

10 李長東;張為遠(yuǎn);苑春莉;韓麗英;;卵巢癌細(xì)胞對人樹突狀細(xì)胞成熟及功能的影響[A];中華醫(yī)學(xué)會第一屆全球華人婦產(chǎn)科學(xué)術(shù)大會暨第三次全國婦產(chǎn)科中青年醫(yī)師學(xué)術(shù)會議論文匯編[C];2007年

相關(guān)重要報紙文章 前4條

1 記者 任海軍;卵巢癌為何常常復(fù)活？生死命懸一基因[N];新華每日電訊;2009年

2 靖九江;4-HPR有望用于治療卵巢癌[N];中國醫(yī)藥報;2005年

3 邰 舉;韓國醫(yī)學(xué)專家發(fā)現(xiàn)精液能夠殺死卵巢癌細(xì)胞[N];中國中醫(yī)藥報;2003年

4 邰舉;精液能夠殺死卵巢癌細(xì)胞[N];科技日報;2003年

相關(guān)博士學(xué)位論文 前10條

1 王萍;丙泊酚對卵巢癌細(xì)胞侵襲和紫杉醇誘導(dǎo)的卵巢癌細(xì)胞凋亡的作用中轉(zhuǎn)錄因子Slug的影響[D];山東大學(xué);2015年

2 魏星;CGI-58基因調(diào)控脂代謝介導(dǎo)卵巢癌細(xì)胞侵襲轉(zhuǎn)移的作用及機(jī)制研究[D];第三軍醫(yī)大學(xué);2015年

3 項喜艷;去乙�；窼IRT3調(diào)控卵巢癌細(xì)胞代謝增加BH3模擬物S1凋亡敏感性的研究[D];吉林大學(xué);2016年

4 楊秋云;NEDD4L在卵巢上皮癌的表達(dá)及作用研究[D];吉林大學(xué);2016年

5 王燕;糖皮質(zhì)激素對卵巢癌細(xì)胞遷移和侵襲的影響及其機(jī)制研究[D];第二軍醫(yī)大學(xué);2016年

6 龍啟芳;腫瘤干細(xì)胞靶向殺傷病毒表達(dá)系統(tǒng)對卵巢癌細(xì)胞生物學(xué)性狀影響的研究[D];南京醫(yī)科大學(xué);2017年

7 趙U，

本文編號：2324739